2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

4051 Effect of frailty markers on response to CAR-T cell therapy in relapsed refractory multiple myeloma

Heidi Vieira, MD, PhD, Elizabeth Lyden, MS2, Tanya Wildes, MD,MSc3, Julie Vose, MD4, Christopher D'Angelo, MD, MS5
1 University of Nebraska Medical Center, Omaha, Nebraska, United States, University of Washington, Seattle, Washington, United States
2 University of Nebraska Medical Center, Omaha, Nebraska, United States
3 University of Nebraska Medical Center, Omaha, Nebraska, United States
4 University of Nebraska Medical Center, Omaha, Nebraska, United States
5 University of Nebraska Medical Center, Omaha, Nebraska, United States

Background: Frailty is associated with an increased risk of toxicities and poor treatment outcomes after CAR-T cell therapy. Robust measures to identify frailty, including comprehensive geriatric assessments, may be difficult to incorporate for all patients in a tight CAR-T timeline, and simple tools to identify frail patients prior to CAR-T may help guide treatment strategies and discussion. The Glasgow Prognosis Score (GPS) is a simple test combining low albumin (<3.5 g/L) and high C-reactive protein (CRP, >10 mg/L), where high scores predict increased toxicities and impaired outcomes with cancer therapy. Prior reports (Akhtar et al, TCT 2023) identified an association with high GPS scores and impaired outcomes to BCMA CAR-T, though this analysis was largely restricted to idecabtagene vicleucel (ide-cel) and requires further validation. We hypothesized that markers of frailty including malnutrition, high GPS, and polypharmacy would be associated with impaired outcome including for patients with multiple myeloma receiving CAR T-cell therapy.

Methods: We performed a single-center, retrospective analysis of patients who received CAR-T for relapsed refractory multiple myeloma at the University of Nebraska Medical Center to determine whether pre-treatment indices of frailty affected rates of toxicity, response, progression, and survival after CAR-T. Frailty and comorbidity markers evaluated in our study included GPS, polypharmacy, and malnutrition during CAR T-cell admission, and Charlson comorbidity index. Polypharmacy was defined as >5-7 scheduled medications at time of CAR-T.

Results: Our dataset included 71 patients with median age of 65 (range 33-79) and 31% were females. At diagnosis, 14 patients (23.7%) had R-ISS Stage I disease, 31 (52.5%) had Stage II, and 14 (23.7%) had Stage III. High risk cytogenetics (t (4;14), del17p, t(14;16), t(14;20)) were present in 26 patients (37.7%). At time of CAR-T, 31 patients (44%) had received <4 prior lines of treatment, while 40 (56%) had received ≥4 lines. Most patients (49/71, 69%) received ciltacabtagene autoleucel (cilta-cel), and all others received ide-cel (22/71, 31%).

We first analyzed association of frailty markers with length of stay in hospital for CAR-T, readmission rates, and rates of CAR-T-related toxicity. Malnutrition diagnosed during hospital stay was the only variable associated with increased hospital LOS >11 days (p=0.005). Polypharmacy with >5 meds was associated with PT/OT referral during hospitalization (88% vs 63%, p=0.03) Risk factors associated with cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) were next evaluated after CAR-T. A malnutrition diagnosis was associated with increased risk of CRS (24% vs 4%, p=0.046), while ECOG score ≥2 was a significant predictor of ICANS (31% vs 4% p=0.001).

 Cilta-cel was associated with longer progression-free survival (PFS) compared to ide-cel (HR=0.3, p=0.015). GPS emerged as an independent predictor of PFS and overall survival (OS) after CAR-T. The 1-year estimated PFS was 88% for patients with GPS 0, 61% for GPS 1, and 38% for GPS 2 (p=0.013). Polypharmacy (>7 meds) at time of CAR-T and ECOG ≥2 were also associated with decreased PFS after CAR-T (p=0.049 and p=0.005, respectively).  In multivariate analysis, GPS score of 1-2 strongly impacted PFS after adjusting for other risk factors including R-ISS Stage, cytogenetic risk, and CAR-T product (Hazard Ratio 4.3, p=0.008).

Conclusions: Overall, Glasgow Prognosis Score >0 emerged as the strongest predictor of poorer outcome after CAR-T in our analysis. ECOG score, malnutrition status, and polypharmacy correlated with the risk of CAR-T-related toxicities. These data support findings from other studies that GPS and frailty markers can contribute to risk stratification for CAR-T therapy in multiple myeloma and suggest future directions for continued study to optimize CAR-T outcomes.

Heidi Vieira, MD, PhD: No relevant conflicts of interest to declare.